Aardvark Posts Q2 Loss, Ends Pivotal Trials, and Extends Cash Runway into Late 2027

summarizeSummary

Aardvark Therapeutics reported Q2 2026 financial results, terminated its two Phase 3 trials for ARD-101, and is assessing unblinded data to decide next steps. Cash of $73.9 million funds operations into late 2027.

check_boxKey Events · Earnings and Guidance · AARD

• Phase 3 Trials Terminated

  In June 2026, the HERO and OLE Phase 3 trials for ARD-101 were terminated, and the company has no plans to resume them as previously designed—effectively ending the current pivotal program for its lead asset.

• Q2 2026 Financial Results

  A net loss of $14.4 million was recorded on operating expenses of $15.1 million. R&D expenses fell to $10.5 million from $13.1 million a year ago due to trial pauses, while G&A rose to $4.6 million from $2.7 million, including severance costs from a June workforce reduction.

• Cash Runway into Late 2027

  Cash, equivalents, and short-term investments totaled $73.9 million as of June 30, 2026, down from $91.2 million at March 31, 2026. Management expects this to fund operations into late 2027.

• Unblinded Data Assessment in Q3

  During Q3 2026, the company is assessing unblinded efficacy and safety data from the terminated trials to inform next steps for the ARD-101 program, while remaining in active discussions with the FDA to resolve the clinical hold.

auto_awesomeAnalysis · AARD · Life Sciences

Aardvark disclosed a $14.4 million net loss for Q2 2026 and, critically, terminated both Phase 3 HERO and OLE trials for its lead drug ARD-101 in June. The company does not intend to resume these trials as previously designed, effectively ending the current pivotal program. With $73.9 million in cash, runway extends into late 2027, but the clinical hold remains unresolved. The company is assessing unblinded data in Q3 to determine next steps, but the termination of these trials represents a major setback for its only late-stage asset.